First AD

Second AD

Myeloproliferative Neoplasms

INC-22-OSD1258 - /clinical/myeloproliferative-neoplasms

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Insights Video Series

My Treatment Approach: Expert Insights Into the Management of Polycythemia Vera

Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.

Managing Toxicities of Hydroxyurea in Patients With PV

Risk Assessment in Patients With Polycythemia Vera (PV)

Reducing Risk of Disease Progression in Patients With PV

Typical Presentation of a Patient With PV

Importance of Bone Marrow Biopsy For Diagnosis of PV

Reducing Risk of Thrombosis in Patients With PV

Factoring Symptom Burden Into Treatment Decision-Making for Patients With PV

Managing Toxicities of Ropeginterferon Alpha-2b in Patients With PV

Key Trials in the Treatment of PV

Treatment Approaches for High-Risk Patients With PV

Influence of Driver Mutations on Response to Ropeginterferon Alpha-2b in Patients with PV

Ruxolitinib in the Treatment of PV

Future Perspectives in the Treatment of Polycythemia Vera